JW Holdings announced on October 24 that it will participate in "Convention on Pharmaceutical Ingredients (CPHI) Worldwide 2023," the world's largest pharmaceutical bio exhibition, to be held in Barcelona, Spain, from October 24 to 26 (local time).
CPHI Worldwide is an exhibition that tours major cities around the world every year and is considered a global exchange event between healthcare companies covering not only raw materials and finished pharmaceutical products, but also pharmaceutical packaging materials, facilities, and logistics. This year's event will be attended by more than 47,000 industry stakeholders from more than 150 countries around the world.
JW Holdings will have an exclusive booth at the event, where it will introduce medicines from its competitive business companies, including JW Pharmaceutical and JW Life Science, and raise its profile in the global market. In addition, the company will focus on promoting its major product lines, including specialty and over-the-counter medicines, to potential customers in the European market.
In addition, the company will showcase its pharmaceutical plants, specialized systems and know-how to operate them, and promote its contract manufacturing (CMO) and contract development and manufacturing (CDMO) capabilities to global customers.
Since entering the European market in 2018, which is said to be the home of total parenteral nutrition, JW Holdings has been securing its competitiveness in the global market by exporting the three-chamber total parenteral nutrition (TPN) "Winuf" produced by JW Life Science and continuing local sales.
"JW Group is striving to expand its influence in the European market based on its long-standing global competitiveness," said an official from JW Holdings. "Through this event, we will strengthen collaboration with global partners and promote JW Group's excellent pharmaceutical products to the global market."
